Compare Moderna, Inc. (MRNA) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Starbucks Corp — how do they compare? Moderna, Inc. trades at $63.75 (market cap $24.18B), while Starbucks Corp trades at $108.12 (market cap $121.59B). The key difference: Starbucks Corp is far larger — about 5× Moderna, Inc.'s market cap, and Starbucks Corp pays a 2.33% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | SBUX | |
|---|---|---|
Market Cap | $24.18B | $121.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $81.80 | $108.37 |
52-Week Low | $22.36 | $78.46 |
Enterprise Value | $20.33B | $140.42B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.
The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.
Starbucks (SBUX) trades at $108.03, up 3.23% with strong technical momentum and bullish moving average signals. The company shows improving fundamentals with recent earnings beats and raised 2026 guidance, though valuation remains elevated at a P/E of 61.65. Recent news highlights a successful turnaround strategy under CEO Brian Niccol, with traffic recovery and margin expansion driving optimism.
The outlook remains positive with analyst consensus pointing to $113.60 price target, though high valuation and execution risks require monitoring. Key opportunities include sustained traffic growth and cost efficiency initiatives, while risks involve premium pricing sensitivity and competitive pressures in the coffee retail space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
